ArticleClinical rheumatology2026
USP14-mediated inhibition of CDH11 ubiquitination propels IL-1β-induced chondrocyte injury.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a chronic joint disease, osteoarthritis (OA) severely impairs patients' quality of life and mobility. The deubiquitinating enzyme USP14 and Cadherin-11 (CDH11) have been implicated in OA pathogenesis. However, the regulatory interplay between them remains poorly defined.
methodsIL-1β was used to stimulate chondrocytes for in vitro OA model establishment. Bioinformatics database was employed to assess CDH11 expression in OA samples. MTT assay was performed to evaluate cell viability. Protein expression was analyzed via Western blot. Cell apoptosis was detected by flow cytometry. Levels of ROS, GSH, MDA, Fe
resultsCDH11 expression was upregulated in OA samples and IL-1β-induced chondrocytes. Moreover, silencing CDH11 promoted cell viability and attenuated cell apoptosis, inflammation, oxidative stress, and ferroptosis. USP14 stabilized CDH11 through deubiquitination, sustaining CDH11-mediated chondrocyte damage. After USP14 knockdown, cell viability was increased, while cell apoptosis, inflammation, oxidative stress and ferroptosis were mitigated. Furthermore, CDH11 overexpression abrogated the effects of USP14 knockdown on IL-1β-stimulated chondrocytes.
conclusionUSP14 mediates IL-1β-induced chondrocyte injury by stabilizing CDH11 through deubiquitination, highlighting the USP14-CDH11 axis as a potential regulatory pathway in OA-related chondrocyte pathology. Key Points • CDH11 is highly expressed in OA samples and IL-1β-induced chondrocytes.. • Silencing CDH11 inhibits IL-1β-induced cell injury, oxidative stress and ferroptosis, confirming CDH11 as a pro-injury factor for chondrocytes. • USP14 stabilizes CDH11 through deubiquitination. • Overexpression of CDH11 reverses the effects of USP14 knockdown on IL-1-induced chondrocytes.
Indexed as
Identifiers
41653235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.